SIMLANDI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SIMLANDI (SIMLANDI).
SIMLANDI (adalimumab-adbm) is a tumor necrosis factor (TNF) blocker. It binds to TNF-alpha and inhibits its interaction with the p55 and p75 cell surface TNF receptors, thereby reducing inflammatory responses.
| Metabolism | Adalimumab-adbm is a monoclonal antibody; it is degraded into small peptides and amino acids via catabolic pathways, not metabolized by cytochrome P450 enzymes. |
| Excretion | Adalimumab is eliminated primarily via catabolism to small peptides and amino acids; renal excretion of intact drug is negligible (<1%). Biliary/fecal excretion of intact drug is minimal. |
| Half-life | Terminal elimination half-life is approximately 14 days (range 10–20 days) in patients with rheumatoid arthritis; this supports a subcutaneous dosing interval of every other week. |
| Protein binding | Approximately 95% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Apparent volume of distribution is approximately 4.7–6.0 L after subcutaneous administration, suggesting limited extravascular distribution; Vd is not typically expressed per kg in clinical context. |
| Bioavailability | Subcutaneous: 64% (absolute bioavailability). |
| Onset of Action | Subcutaneous: Clinical improvement may be observed within 1–2 weeks, with maximal effect typically achieved by 12–24 weeks. |
| Duration of Action | Following a single subcutaneous dose, therapeutic serum concentrations persist for approximately 2–3 weeks; clinical effect may persist beyond serum presence due to immunomodulatory mechanisms. |
Subcutaneous injection, 40 mg every 2 weeks; may increase to 40 mg weekly if no response within 4 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (CrCl <15 mL/min) or ESRD; use with caution. |
| Liver impairment | No dose adjustment required for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Not recommended in severe hepatic impairment (Child-Pugh C) due to lack of data. |
| Pediatric use | For juvenile idiopathic arthritis (age ≥2 years): weight <30 kg: 20 mg subcutaneously every 2 weeks; weight ≥30 kg: 40 mg subcutaneously every 2 weeks. |
| Geriatric use | No specific dose adjustment recommended; higher incidence of infections and malignancies in elderly patients. Monitor closely for adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SIMLANDI (SIMLANDI).
| Breastfeeding | Adalimumab is excreted in human breast milk in low concentrations. The M/P ratio is not explicitly reported for adalimumab, but the relative infant dose is estimated to be approximately 0.1-1% of the maternal dose. No adverse effects have been reported in breastfed infants. Caution is advised in premature infants or those with renal impairment. Current guidelines consider adalimumab compatible with breastfeeding. |
| Teratogenic Risk | SIMLANDI (adalimumab-atto) is a tumor necrosis factor (TNF) blocker. Based on available data from the Organization of Teratology Information Specialists (OTIS) autoimmune diseases in pregnancy study, adalimumab does not show an increased risk of major birth defects or miscarriage. However, TNF blockers cross the placenta in the third trimester and may affect fetal immune response. The risk of malformations is not significantly increased; data are insufficient for rare outcomes. |
■ FDA Black Box Warning
WARNING: SERIOUS INFECTIONS and MALIGNANCY. Patients treated with adalimumab products are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), invasive fungal infections, and other opportunistic infections. Malignancies, including lymphoma, have been reported in children and adolescents treated with TNF blockers.
| Serious Effects |
["Known hypersensitivity to adalimumab-adbm or any inactive ingredient","Active, serious infections including localized infections"]
| Precautions | ["Serious infections (including TB, bacterial sepsis, invasive fungal infections)","Hepatitis B virus reactivation","Neurologic reactions (e.g., demyelinating disorders)","Hematologic reactions (pancytopenia, aplastic anemia)","Congestive heart failure (worsening or new onset)","Lupus-like syndrome","Malignancies (lymphoma, leukemia, other malignancies)","Hypersensitivity reactions (including anaphylaxis)"] |
Loading safety data…
| Fetal Monitoring | Monitor for maternal infections, including tuberculosis reactivation, and fetal growth. Consider fetal ultrasound for growth assessment if used in the second/third trimester. Live vaccines should not be administered to infants exposed in utero for at least 5 months post-delivery. No specific fetal heart rate monitoring required. |
| Fertility Effects | Adalimumab does not appear to impair fertility in animal studies. In humans, no negative impact on fertility has been reported; however, TNF blockers may reduce inflammation in conditions like rheumatoid arthritis, potentially improving fertility by controlling disease activity. |